This bill establishes a Pharmacy Benefits Manager (PBM) and Third-Party Administrator Oversight Work Group to address prescription drug costs and healthcare expenses in Virginia. The Work Group, convened by the Secretary of Health and Human Resources and in consultation with the Attorney General, will examine the implications of a 2020 Supreme Court case (Rutledge v. PCMA) and develop legislative recommendations. The Work Group’s objectives include investigating PBM and third-party administrator practices, identifying ways to reduce drug costs, enhance healthcare transparency, and improve health outcomes. The group will comprise representatives from various state agencies, the pharmaceutical industry, consumer advocacy groups, and healthcare professionals. They are tasked with conducting hearings, gathering data, and consulting experts to develop comprehensive strategies. A key focus will be exploring opportunities to promote generic drug manufacturing, particularly in collaboration with research institutions like the Medicines for All Institute at Virginia Commonwealth University. The Work Group is required to submit a detailed report to the General Assembly by November 1, 2026, which must include specific legislative proposals and recommendations for supporting generic drug manufacturing in the state.